Bunge Limited
BG
$126.36
+1.87%
Bunge Global SA is a leading global agribusiness and food solutions company, operating in the Agricultural Farm Products sector by connecting farmers to consumers and delivering essential food, feed, and fuel. The company is a major player in the global agricultural supply chain, distinct for its integrated operations spanning soybean and softseed processing, grain merchandising, and milling. The current investor narrative is focused on the company's ambitious long-term financial targets, including a goal for $15 in mid-cycle EPS by 2030, which signals strong management confidence in its strategic direction despite facing near-term volatility in agricultural commodity markets and processing margins.…
BG
Bunge Limited
$126.36
Related headlines
Investment Opinion: Should I buy BG Today?
Rating: Hold. The core thesis is that BG's attractive forward valuation and long-term targets are compelling, but they are currently overshadowed by severe near-term margin pressure and earnings volatility, warranting caution before establishing new positions.
Supporting evidence includes a forward P/E of 11.9x, which is a 34% discount to the trailing P/E of 18.1x and prices in a significant earnings recovery to an estimated $11.06 EPS. The stock trades at deep discounts on sales-based metrics (P/S of 0.21, EV/Sales of 0.57) relative to the consumer defensive sector. However, profitability metrics are weak, with Q4 net margin at 0.40% and ROE at 4.70%. The unanimous 'Buy' ratings from major institutions provide sentiment support, but the low analyst count (3) and high short interest (ratio of 2.78) introduce uncertainty.
The thesis would upgrade to a Buy if QoQ gross margins show a clear recovery above 5% or if the stock pulls back to the $110-$115 range, offering a better risk/reward entry. It would downgrade to a Sell if Q4 margin compression proves not to be a trough and net margins fall below 0.3% in the next quarter, or if the stock breaks below key technical support near $115. On balance, the stock appears fairly valued relative to its near-term challenges but undervalued relative to its long-term potential, creating a 'wait-and-see' scenario.
Sign up to view all
BG 12-Month Price Forecast
The outlook for BG is bifurcated between a promising long-term narrative and difficult near-term fundamentals. The base case (50% probability) of range-bound trading is most likely, as the market digests the margin weakness while giving some credit to the forward valuation and strategic targets. The stance is neutral due to this conflict; the stock is not expensive, but the fundamental deterioration warrants caution. The stance would turn bullish on clear evidence of margin stabilization or expansion in the next quarterly report. It would turn bearish if the next earnings release shows further margin contraction, validating short-seller skepticism and likely leading to a derating.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bunge Limited's 12-month outlook, with a consensus price target around $164.27 and implied upside of +30.0% versus the current price.
Average Target
$164.27
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$101 - $164
Analyst target range
Analyst coverage for Bunge is limited, with only 3 analysts providing estimates, which is low for a company of its market cap and can lead to higher volatility and less efficient price discovery. The available data shows consensus estimates for EPS averaging $11.06 for the period, with a range from $10.42 to $11.64, and revenue estimates averaging $97.2 billion. The institutional ratings data, while not providing a formal consensus or price target, shows a uniformly bullish sentiment among major firms; recent actions from JP Morgan, Morgan Stanley, Barclays, UBS, and BMO Capital all maintain 'Overweight', 'Outperform', or 'Buy' ratings. This pattern of sustained bullish recommendations from key institutions, despite limited quantitative target data, indicates strong professional conviction in the stock's long-term story, likely tied to its strategic goals and market position.
Bulls vs Bears: BG Investment Factors
The investment debate for Bunge hinges on the tension between its compelling long-term strategic narrative and severe near-term cyclical headwinds. The bull case is supported by strong institutional conviction, an attractive forward valuation anticipating an earnings rebound, and ambitious 2030 targets. The bear case is grounded in the harsh reality of collapsing quarterly profitability, extreme earnings volatility inherent to the commodity business, and low returns on capital. Currently, the bearish evidence from deteriorating fundamentals carries more weight in the immediate term, as the stock's recent rally appears disconnected from the sharp margin compression reported in Q4. The single most important factor is the resolution of processing margins; a sustained recovery would validate the forward P/E and long-term targets, while continued pressure would expose the stock's elevated price as unsustainable.
Bullish
- Strong Institutional Conviction: Major investment banks including JP Morgan, Morgan Stanley, Barclays, UBS, and BMO Capital all maintain 'Overweight' or 'Buy' ratings on BG. This unanimous bullish sentiment from key institutions, despite limited analyst coverage, signals strong professional confidence in the company's long-term strategic goals and market position.
- Attractive Forward Valuation: The stock trades at a forward P/E of 11.9x based on analyst EPS estimates of $11.06, which is a significant discount to its trailing P/E of 18.1x. This forward multiple suggests the market is pricing in a meaningful earnings recovery, offering a compelling entry point if the company executes.
- Robust Long-Term Price Momentum: BG has delivered a 54.6% total return over the past year, significantly outperforming the S&P 500's 30.6% gain. The stock is trading near its 52-week high of $131.93, indicating sustained bullish momentum and a breakout from its historical trading range.
- Solid Balance Sheet & Low Beta: With a debt-to-equity ratio of 0.98 and a current ratio of 1.61, BG maintains a manageable financial structure with good liquidity. Its beta of 0.70 indicates approximately 30% less volatility than the broader market, providing a defensive characteristic for a commodity-linked stock.
Bearish
- Severe Profitability Compression: Q4 2025 net income plummeted to $95M from $166M in Q3, with net margin collapsing to 0.40% from 0.75%. Gross margin also fell to 4.25% from 4.80%, reflecting intense pressure in agricultural processing margins that directly impacts earnings power.
- Extreme Revenue & Earnings Volatility: Revenue surged 75.5% YoY in Q4 2025 but followed a sharp sequential decline, highlighting the inherent cyclicality of the business. EPS has swung wildly from $4.49 in Q4 2024 to $0.49 in Q4 2025, making consistent earnings forecasts highly challenging.
- Low Return on Capital: Return on Equity (ROE) stands at a modest 4.70% and Return on Assets (ROA) at 2.51%. These figures reflect the low-margin, capital-intensive nature of the agribusiness model and raise questions about the efficiency of capital allocation relative to other sectors.
- Limited Analyst Coverage & High Short Interest: Only 3 analysts provide estimates for BG, which can lead to less efficient price discovery and higher volatility. A short ratio of 2.78 indicates a significant level of skepticism among short sellers, who are betting against the stock's recent rally.
BG Technical Analysis
The stock is in a sustained uptrend, evidenced by a robust 54.58% gain over the past year. As of the latest close at $124.90, the price is trading at approximately 95% of its 52-week high of $131.93, positioning it near the top of its annual range and indicating strong momentum, though also raising questions about potential overextension. Recent momentum shows a deceleration from the longer-term trend; while the 3-month return is a solid 9.95%, the 1-month return is negative at -0.40%, suggesting a short-term consolidation or pullback after the significant rally. This divergence could signal a healthy pause for the stock to digest its gains before potentially resuming its upward trajectory. Key technical levels are clearly defined, with immediate support at the 52-week low of $71.60 and resistance at the 52-week high of $131.93. A decisive breakout above $131.93 would confirm the bullish trend's continuation, while a breakdown below recent lows could signal a deeper correction. With a beta of 0.696, the stock exhibits approximately 30% less volatility than the broader market (SPY), which is notable for a commodity-linked business and suggests it may offer a more defensive profile within the sector.
Beta
0.70
0.70x market volatility
Max Drawdown
-15.4%
Largest decline past year
52-Week Range
$72-$132
Price range past year
Annual Return
+56.7%
Cumulative gain past year
| Period | BG Return | S&P 500 |
|---|---|---|
| 1m | -1.8% | +12.2% |
| 3m | +9.6% | +2.3% |
| 6m | +32.8% | +4.7% |
| 1y | +56.7% | +29.2% |
| ytd | +36.4% | +4.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BG Fundamental Analysis
Revenue growth has been volatile but showed a significant year-over-year increase of 75.47% in the most recent quarter (Q4 2025), reaching $23.76 billion, though this follows a sharp sequential decline from the prior quarter's $22.16 billion. The multi-quarter trend reveals high volatility typical of commodity processors, with revenue peaking in Q2 2025 at $12.77 billion before surging in Q4, indicating sensitivity to crop cycles and pricing. Profitability metrics are under pressure; the company reported net income of $95 million in Q4 2025, a sharp drop from $166 million in Q3, with a corresponding net margin compression to 0.40% from 0.75%. Gross margin for the quarter was 4.25%, down from 4.80% in Q3, reflecting the challenging margin environment in agricultural processing. The balance sheet and cash flow position show a solid financial structure; the debt-to-equity ratio is a manageable 0.98, and the current ratio is a healthy 1.61, indicating good short-term liquidity. Trailing-twelve-month free cash flow is $296 million, providing internal funding capacity, while the Return on Equity (ROE) of 4.70% and Return on Assets (ROA) of 2.51% reflect modest but positive returns on capital employed.
Quarterly Revenue
$23.8B
2025-12
Revenue YoY Growth
+0.75%
YoY Comparison
Gross Margin
+0.04%
Latest Quarter
Free Cash Flow
$296000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BG Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio stands at 18.12x, while the forward PE is notably lower at 11.90x, indicating the market expects a significant earnings recovery in the coming year. Compared to sector averages, Bunge's valuation presents a mixed picture; its Price-to-Sales (PS) ratio of 0.21 is extremely low, and its Enterprise Value-to-Sales (EV/Sales) of 0.57 suggests a discount relative to many consumer defensive peers, which often trade at higher sales multiples. The discount may reflect the cyclical and low-margin nature of the agribusiness model versus more stable packaged food companies. Historically, the stock's own valuation has fluctuated widely; the current trailing PE of 18.12x is below the recent historical high of 45.71x seen in Q4 2025 but above the low of 4.46x from Q4 2024. This places it in a mid-range relative to its own history, suggesting the market is pricing in a moderate recovery scenario rather than peak cycle optimism or deep distress.
PE
18.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~54x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced, centered on severe margin volatility and low profitability. Q4 2025 net margin compressed to 0.40%, down from 0.75% in Q3 and a peak of 4.45% in Q4 2024, demonstrating extreme sensitivity to commodity crush spreads. The business model is capital-intensive with modest returns, as evidenced by a 4.70% ROE and 2.51% ROA. While the balance sheet is stable with a 0.98 debt-to-equity ratio, the company's earnings are highly dependent on favorable agricultural commodity cycles, and a failure to achieve its projected EPS recovery would pressure the valuation.
Market & Competitive Risks include valuation compression if the anticipated earnings rebound fails to materialize. The stock trades at a forward P/E of 11.9x, which is a discount to its own trailing multiple but could re-rate lower if forward estimates are cut. As a commodity processor, BG faces competitive pressures on volume and margins from global peers. Its low beta of 0.70 offers some defensive quality, but the stock remains susceptible to sector rotation out of cyclical names if macroeconomic growth concerns intensify.
Worst-Case Scenario involves a prolonged downturn in global agricultural processing margins, triggered by oversupply or weak demand, coupled with a broader market sell-off. This could lead to consecutive quarterly earnings misses, analyst downgrades from the current uniformly bullish stance, and a derating of the forward multiple. The realistic downside could see the stock retracing a significant portion of its 54.6% yearly gain, potentially testing the $71.60 52-week low. From the current price of $124.90, this represents a maximum drawdown of approximately -43%. A more probable severe bear case might see a decline to the $90-$100 range, representing a -20% to -28% loss, as the market prices in a deeper cyclical trough.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: Extreme volatility and compression in processing margins, as seen with the Q4 net margin drop to 0.40%, which directly threatens earnings. 2) Cyclical/Commodity Risk: Revenue and earnings are highly dependent on unpredictable agricultural commodity prices and global trade flows. 3) Execution Risk: The company may fail to execute on its strategic plan and achieve the ambitious $15 EPS by 2030 target, leading to multiple contraction. 4) Sentiment & Liquidity Risk: With only 3 analysts providing estimates, price discovery can be inefficient, and the high short interest (ratio 2.78) indicates a pool of ready sellers.
The 12-month forecast is framed by three scenarios. The Base Case (50% probability) sees the stock trading between $125 and $135, as it digests near-term challenges while supported by its valuation. The Bull Case (30% probability), driven by margin recovery, targets $140-$155. The Bear Case (20% probability), triggered by worsening fundamentals, sees a decline to $90-$110. The base case is most likely, anchored by the analyst EPS estimate of $11.06 and a forward P/E around 11.9x. The key assumption is that the severe margin pressure from Q4 2025 represents a cyclical trough, not a new normal.
BG's valuation is sending mixed signals, but on balance, it appears fairly valued to slightly undervalued based on forward estimates. The trailing P/E of 18.1x is not cheap for a company with 4.7% ROE, but the forward P/E of 11.9x is compelling if the analyst consensus for ~$11.06 EPS is achieved. The stock trades at a deep discount on sales multiples (P/S of 0.21), typical for low-margin commodity businesses. Compared to its own history, the current trailing P/E is in a mid-range between the high of 45.7x and low of 4.5x. The valuation implies the market is paying a fair price for a anticipated earnings recovery, but is not assigning a premium for the long-term growth story yet.
BG presents a nuanced risk/reward profile. For investors with a long-term horizon (3+ years) and a tolerance for volatility, the current forward P/E of 11.9x and the ambitious $15 EPS 2030 target could represent a good buying opportunity on any significant pullback. However, given the severe margin compression evidenced in the latest quarter (net margin fell to 0.40%) and the stock's proximity to its 52-week high, it is not an ideal buy at this moment. A more prudent approach would be to wait for either a better entry price (closer to $115) or confirmation that the margin downturn has bottomed. It is a better buy for cyclical investors than for those seeking stable growth or income.
BG is unequivocally suited for a long-term investment horizon, with a suggested minimum holding period of 3-5 years. This timeframe is necessary to ride out the inherent commodity cycle volatility and allow management's long-term strategic initiatives, including the $15 EPS by 2030 goal, to potentially bear fruit. The stock's low beta of 0.70 suggests it is less volatile than the market, which supports a holding strategy, but its quarterly earnings are highly unpredictable, making it a poor candidate for short-term trading. The modest 3.1% dividend yield provides a small income component for patient holders.